Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.41 |
| ▸ | ELANE | P08246 | 1/20 | 0.39 |
| ▸ | ACE | P12821 | 3/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.39 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.38 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | BTK | Q06187 | 1/20 | 0.38 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.36 |
| ▸ | PREP | P48147 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1782216 | 1.00 | HSD17B10 (0.44) | HSD17B10NR1H2ELANEACESMN1; SMN2 | |
| SCHEMBL8353685 | 1.00 | HSD17B10 (0.44) | HSD17B10NR1H2ELANEACESMN1; SMN2 | |
| SCHEMBL13305759 | 1.00 | HSD17B10 (0.44) | HSD17B10NR1H2ELANEACESMN1; SMN2 | |
| SCHEMBL5207425 | 1.00 | HSD17B10 (0.44) | HSD17B10NR1H2ELANEACESMN1; SMN2 | |
| SCHEMBL7876562 | 1.00 | HSD17B10 (0.44) | HSD17B10NR1H2ELANEACESMN1; SMN2 | |
| SCHEMBL7872099 | 1.00 | HSD17B10 (0.44) | HSD17B10NR1H2ELANEACESMN1; SMN2 | |
| SCHEMBL1782218 | 1.00 | HSD17B10 (0.44) | HSD17B10NR1H2ELANEACESMN1; SMN2 | |
| SCHEMBL24113374 | 0.99 | HSD17B10 (0.45) | HSD17B10NR1H2ELANEACESMN1; SMN2 | |
| SCHEMBL25362467 | 0.99 | HSD17B10 (0.45) | HSD17B10NR1H2ELANEACESMN1; SMN2 | |
| SCHEMBL3700523 | 0.93 | HSD17B10 (0.45) | HSD17B10NR1H2ELANESMN1; SMN2EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250346585-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ALEXION PHARMACEUTICALS, INC. (US) | 2025-11-13 | — | — | US | disclosed |
| CN-115066417-B | Factor XIa inhibitors | 上海京新生物医药有限公司 | 2025-05-02 | — | — | CN | disclosed |
| WO-2023183405-A2 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ALEXION PHARMACEUTICALS, INC. (US) | 2023-09-28 | — | — | WO | disclosed |
| CN-115066417-A | Factor XIa inhibitors | 上海京新生物医药有限公司 | 2022-09-16 | — | — | CN | disclosed |
| EP-1389200-A4 | SUBSTITUTED N-ARYLSULFONYL-PROLINE DERIVATIVES AS POTENT CELL ADHESION INHIBITORS | MERCK & CO INC (US) | 2007-03-28 | — | — | EP | disclosed |
| US-6943180-B2 | Substituted N-arylsulfonyl-proline derivatives as potent cell adhesion inhibitors | MERCK & CO., INC. (US) | 2005-09-13 | — | — | US | disclosed |
| US-20040102478-A1 | Substituted n-arylsulfonyl-proline derivatives as potent cell adhesion inhibitors | MERCK & CO., INC. | 2004-05-27 | — | — | US | disclosed |
| EP-1389200-A1 | SUBSTITUTED N-ARYLSULFONYL-PROLINE DERIVATIVES AS POTENT CELL ADHESION INHIBITORS | Merck & Co., Inc. (US) | 2004-02-18 | — | — | EP | disclosed |
| WO-2002074761-A1 | SUBSTITUTED N-ARYLSULFONYL-PROLINE DERIVATIVES AS POTENT CELL ADHESION INHIBITORS | MERCK & CO., INC. (US) | 2002-09-26 | — | — | WO | disclosed |
| US-6329502-B1 | VIRICIDES AGAINST HUMAN IMMUNODEFICIENCY VIRUS; TREATMENT OF AIDS (ACQUIRED IMMUNE DEFICIENCY SYNDROME) | JAPAN ENERGY CORPORATION (JP) | 2001-12-11 | — | — | US | disclosed |
| US-6313094-B1 | COMPOSITION FOR INHIBITING HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | JAPAN ENERGY CORPORATION (JP) | 2001-11-06 | — | — | US | disclosed |
| EP-0490667-B1 | HIV protease inhibitors | JAPAN ENERGY CORP (JP) | 1999-06-09 | — | — | EP | disclosed |
| EP-0490667-A2 | HIV protease inhibitors | JAPAN ENERGY CORPORATION (JP) | 1992-06-17 | — | — | EP | disclosed |
| EP-0053902-B1 | PHOSPHINYLALKANOYL SUBSTITUTED PROLINES | E.R. Squibb & Sons, Inc. (US) | 1985-04-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250346585-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | C5, C1S, C9 | HSD17B10 2484/4885NR1H2 2093/4885ELANE 72/4885 |
| US-20040102478-A1 | Substituted n-arylsulfonyl-proline derivatives as potent cell adhesion inhibitors | VCAM1, CD4, ICAM1 | HSD17B10 3819/4885NR1H2 1321/4885ELANE 2794/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.